Cencora, Inc. (BIT:1COR)
Italy · Delayed Price · Currency is EUR | Market Cap | 51.39B +1.0% |
| Revenue (ttm) | 291.27B +5.1% |
| Net Income | 2.30B +38.3% |
| EPS | 11.78 +39.1% |
| Shares Out | n/a |
| PE Ratio | 22.37 |
| Forward PE | 15.72 |
| Dividend | 2.06 (0.74%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 2 |
| Open | 288.90 |
| Previous Close | 268.20 |
| Day's Range | 277.80 - 288.90 |
| 52-Week Range | 213.30 - 330.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
Cencora appoints Robert Sanchez to board of directors
Cencora (COR) announced that its Board of Directors has elected Robert Sanchez as a new independent director, effective October 1. Sanchez is the Executive Chair of Ryder System, Inc., where…
Cencora Elects Robert E. Sanchez to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sa...
Cencora Transcript: 2026 Global Healthcare Conference
Leadership highlighted a smooth CFO transition, a focus on specialty pharma and MSO growth, and disciplined capital deployment. MSOs are expected to drive profitability by 2027, with stable customer relationships and no major strategic shifts planned.
Cencora sees ‘wraparound’ impact in 2027 from Walgreens
Says Walgreens “has been an important strategic partner for us over a long period of time. We have an excellent relationship with their new team, and we will continue to…
Cencora Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynamics are being managed proactively, with capital allocation priorities unchanged.
Cencora Transcript: Wells Fargo 21st Annual Healthcare Conference
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and MSO expansion offer future opportunities. Independent pharmacies remain resilient.
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solution...
Cencora initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Cencora (COR) with a Sector Perform rating and $330 price target The company’s “pharma-aligned and integrated platform” will benefit from growth in specialty pharma, ...
Cencora still sees FY26 adjusted EPS $17.75-$17.95, consensus $17.86
12:44 EDT Cencora (COR) still sees FY26 adjusted EPS $17.75-$17.95, consensus $17.86
Cencora says some Walgreens volume moving outside company
Says prime vendor pact is unchanged. Says development fully contemplated in guidance.
Cencora says some Walgreens volume moving away, affirms outlook
Cencora (COR) disclosed that beginning July 1, certain Walgreens volume that was being serviced by Cencora separate from the prime vendor agreement began moving outside the company. “The prime vendor…
Leerink sees Cencora’s loss of part of Walgreens business as ‘fairly limited’
Leerink says that losing any business from the largest customer such as Cencora (COR) did with Walgreens is never good. With that said, the firm believes the magnitude incorporated in…
Cencora price target raised to $346 from $342 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cencora (COR) to $346 from $342 and keeps an Overweight rating on the shares.
Cencora price target raised to $370 from $340 at Baird
Baird raised the firm’s price target on Cencora (COR) to $370 from $340 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and…
Cencora price target raised to $430 from $412 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Cencora (COR) to $430 from $412 and keeps a Buy rating on the shares.
Cencora price target raised to $350 from $330 at Evercore ISI
Evercore ISI raised the firm’s price target on Cencora (COR) to $350 from $330 and keeps an Outperform rating on the shares.
Cencora price target raised to $370 from $355 at Citi
Citi raised the firm’s price target on Cencora (COR) to $370 from $355 and keeps a Buy rating on the shares. The firm views the company’s earnings report as solid.
Cencora Earnings Call Transcript: Q3 2026
Q3 saw strong double-digit adjusted operating income and EPS growth, driven by specialty and MSO performance, the OneOncology acquisition, and robust capital deployment. Fiscal 2026 guidance was raised, with continued momentum expected across U.S. and international segments.
Cencora Earnings release: Q3 2026
Cencora released its Q3 2026 earnings on August 5, 2026, summarizing the period's financial results.
Cencora Slides: Q3 2026
Cencora has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 5, 2026.
Cencora Quarterly report: Q3 2026
Cencora has published its Q3 2026 quarterly earnings report on August 5, 2026.
Cencora lifts annual profit view on strong demand for specialty medicines
U.S. drug distributor Cencora raised its annual adjusted profit forecast on Wednesday after quarterly results beat Wall Street expectations, driven by strong demand for specialty medicines.
Cencora reports Q3 adjusted EPS $4.48, consensus $4.35
Reports Q3 revenue $84.8B, consensus $84.15B. “Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members. Our strong performanc...
Cencora raises FY26 adjusted EPS view to $17.75-$17.95 from $17.70-$17.90
FY26 consensus $17.78. Sees FY26 revenue growth 4%-6%, consensus $336.89B.
Cencora Reports Fiscal 2026 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On...